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Introduction
At 29 weeks of gestation, a pregnant woman in the United States was told that her fetal ultra-
sound had revealed the presence of hydrocephalus. She did not recall having any symptoms or
risk factors during gestation. Serological testing at the national reference laboratory for toxo-
plasmosis in the US (http://www.pamf.org/serology/) confirmed an acute infection likely
acquired around 17 weeks of gestation. She was started on pyrimethamine/sulfadiazine, at 31
weeks. Her amniotic fluid was positive for Toxoplasma gondii DNA by polymerase chain reac-
tion (PCR). The infant was born with hydrocephalus, brain calcifications, and chorioretinitis.
In France, a screening program has been in place since 1992, and pregnant women with nega-
tive serology are tested monthly until delivery. If this pregnant woman had been followed
according to this program, she would have been started on spiramycin 14 weeks earlier than in
the US, her amniotic fluid would have been tested for T. gondii by PCR at 18 weeks, and she
would have been started on pyrimethamine/sulfadiazine 11 to 8 weeks earlier than in the US.
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In the US, such a program does not exist, and infection is usually diagnosed when clinical
signs are present in the fetus or at birth.
Severe disease is not an uncommon situation in the US [1], but it is apparently a rare event
in France (Table 1) [2]. Why is a congenital infection caused by the same parasite approached
so differently in France than in the US? Below, we will discuss several factors that could
account for these diverging approaches.
Parasite Genetics
Approximately 95% of T. gondii strains infecting humans in France are type II (Table 1) [3]. In
contrast, a more heterogeneous distribution of strains is observed in the US. This may reflect
greater migration from South America, where strain types are diverse, or from natural isolates
in the wild, which are more heterogeneous. Sampling, mainly of animal isolates, in North
America indicates that type II represents less than half of the T. gondii strains (43.9%) [4].
Epidemiology
In France, toxoplasmosis seroprevalence has notably decreased in pregnant women, from 83%
in 1965 to 37% in 2010 [5]. Estimation of the incidence of seroconversion during pregnancy
in 2010 was 2.1 per 1,000 susceptible pregnant women [6]. The incidence rate of congenital
toxoplasmosis in 2007 at birth was estimated at 2.9 (95% CI 2.5 to 3.2) per 10,000 live births
(Table 1) [7]. In the US, the seroprevalence of toxoplasmosis among women of childbearing
age (15–44 years) has also declined from 14.9% in a 1988–1994 survey to 9.1% in a 2009–2010
survey. The incidence of T. gondii infection during pregnancy at delivery and 6 weeks postpar-
tum was estimated to be 1.1/1,000 pregnant women [8].The incidence of congenital toxoplas-
mosis, based on results from the New England Newborn Screening Program, was estimated to
be 0.82 cases per 10,000 live births for the period of 1986–1992 [9]. It is currently estimated at
0.5 cases/10,000 live births (see Table 1).
Screening Programs
In France, all susceptible (seronegative) pregnant women are tested monthly until delivery.
The objective is to promptly identify and treat maternal infection in order to prevent fetal
infection and to decrease sequelae in the infected offspring. In the US, pregnant women are
rarely screened for toxoplasmosis. The vast majority of physicians in the US indicate recom-
mend toxoplasmosis testing only for pregnant women who have an abnormal fetal ultrasound
suggestive of congenital infection or, less commonly, have risk factors for acute infection or
present with an illness suggestive of toxoplasmosis. This strategy has been shown to miss at
least half of mothers who give birth to congenitally infected offspring [10]. Newborn screening
for toxoplasmosis is only practiced in Massachusetts and New Hampshire [9].
Treatment
In France, spiramycin is given to mothers as soon as infection is suspected. It is given continu-
ously until delivery unless amniotic fluid PCR turns out to be positive, in which case it is
switched to pyrimethamine/sulfadiazine or pyrimethamine/sulfadoxine. These drugs are given
continuously until delivery. In the US, the approach to treating pregnant women diagnosed
with maternal toxoplasmosis is similar: for infection acquired during the first 18 weeks of ges-
tation or shortly before conception, spiramycin is recommended until delivery [11]. If fetal
infection is confirmed by a positive result in PCR of amniotic fluid, treatment with pyrimeth-
amine/sulfadiazine is recommended (Table 1). Termination of pregnancy (TOP) is an option
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Table 1. Differences in T. gondii genetics, epidemiology, clinical manifestations, and approach to infection detection and management during
pregnancy, between France and the US.
France US
Parasite Genetics Type II: >95%; other types are very rare Type II: 41.5%; non-type II
(including atypicals): 58.5%
IgG Seroprevalence in Women of Childbearing Age 37.0% 9.1%
Incidence of Acute Infection among Toxoplasma-
Seronegative Pregnant Women
2.1/1,000 0.2/1,000*
Incidence of Congenital Toxoplasmosis 2.9/10,000 live births 0.5/10,000 live births*
Clinical Signs of Congenital Toxoplasmosis in Newborns:
Absent, Mild–Moderate, and Severe
85%, 10%, and 3% 12%, 11%, and 77%
Screening of Toxoplasma-Seronegative Pregnant Women Yes. Systematic screening is performed every month No. However, systematic
screening is performed in
some obstetric practices
Diagnosis of Acute T. gondii Infection by Seroconversion Yes, because sequential samples are available Rare
Diagnosis of Acute T. gondii Infection by the Use of a Single
Serum




at reference centers such as
the Palo Alto Medical
Foundation Toxoplasma
Serology Laboratory**
Recommendation of Treatment, Amniotic Fluid for T. gondii
PCR Testing, and Serial Ultrasounds for Acutely Infected
Women
Yes Yes
Indication of Infant’s Workup for Congenital Toxoplasmosis
at Birth
Yes, for each newborn born to a mother infected during gestation regardless
of the presence of clinical signs or laboratory/radiological abnormalities






clinical signs or laboratory/
radiological abnormalities
whose mothers were




Postnatal Treatment of Congenitally Infected Infants Yes, for infected infants of acutely infected pregnant women (symptomatic or
asymptomatic) diagnosed with congenital toxoplasmosis in utero or
postnatally, regardless of the presence of clinical, laboratory, or radiological
abnormalities
Yes, for infants diagnosed
with congenital
toxoplasmosis because of
the presence of clinical signs
in utero or at birth. Seldom,
for infected infants without
clinical, laboratory, or
radiological abnormalities in
whom the diagnosis of
congenital toxoplasmosis
was made in utero or
postnatally because of the
presence of maternal illness,
risk factors, or systematic
screening by an obstetric
practice
Ig, immunoglobulin.
*These estimates are based on data from the New England Newborn Screening Program and not on data from active surveillance. In this program, the
incidence of acute infection among Toxoplasma-seronegative pregnant women and the incidence of congenital infection are underestimated since fetal
losses due to toxoplasmosis during gestation are not included, the filter paper used for screening is only 50% to 75% sensitive, detection of Toxoplasma IgA
is not used, and the actual denominator of women at risk (those who are Toxoplasma seronegative at the beginning of pregnancy) is not known.
**http://www.pamf.org/serology/
doi:10.1371/journal.pntd.0005222.t001
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in France for fetuses with severe manifestations but is rarely performed in France, primarily
because of the progress in prenatal diagnosis and treatment. In the US, approximately 20% of
pregnant women who were told that they had a positive Toxoplasma immunoglobulin (Ig) M
chose TOP before any further confirmatory tests and antenatal diagnosis of fetal infection
were attempted [12].
Prognosis
Congenital toxoplasmosis as managed in France has been reported to have little effect on the
quality of life and visual function of the affected adults [13]. In a cohort of more than 700 con-
genitally infected children, there is no apparent evidence of a higher rate of neuropsychiatric
diseases. During a median follow-up of 10.5 years, 30% of infected children born to treated
mothers developed at least one new ocular lesion [14]. In contrast, in the US, upon long-term
follow-up, 72% of children born to untreated mothers developed a new ocular lesion [15].
Overall, outcomes appear to be better in the era of treatment, even if treatment is instituted
postnatally, than in earlier decades when treatment had not been implemented at all in the US
[1,16]
Discussion
In the case we report here, had the pregnant woman undergone regular screening for toxoplas-
mosis, she would have been told 3 months earlier that she had become infected and would
have been given pyrimethamine/sulfadiazine/folinic acid 13 weeks earlier than in the US.
Would an earlier treatment have changed the outcome of the fetus? Literature from countries
in Europe where the French or French-like approach is followed has steadily reported good
outcomes in children infected with toxoplasmosis when treatment is introduced shortly after
maternal infection [2]. During the same period, literature from the US, where antenatal pro-
grams are lacking, has been reporting infected children with more severe disease and poorer
outcomes [1]. How can we explain such divergent approaches to the same disease? Several fac-
tors like parasite or host genetics and infecting forms could account for this difference. The
presence of antenatal treatment in France and its absence in the US certainly play an important
role. Recent evidence from Europe and France suggests that treatment of toxoplasmosis during
pregnancy is associated with lower transmission rates and decreased sequelae [2]. A meta-anal-
ysis of individual patient data demonstrated that transmission rate was significantly reduced
by half when treatment was introduced 3 weeks versus 8 weeks after the estimated date of
maternal infection [11]. Data from the French Lyon cohort study reported that when monthly
screening was implemented in 1992 and compared to screening before 1992, the risk of fetal
infection fell significantly (for example, at 26 weeks of gestation, it fell from 59.6% to 46.6%;
p = 0.038) [2]. The same study reported that when PCR on amniotic fluid was routinely intro-
duced in 1995 (i.e., infected fetuses were treated earlier with pyrimethamine/sulfadiazine), the
risk of developing clinical signs in children followed for 3 years dropped significantly (odds
ratio [OR] 0.59; 95% CI 0.4 to 0.89; p = 0.012), and the odds of severe neurologic sequelae or
death in infants with congenital toxoplasmosis was also significantly lower (OR 0.24; 95% CI
0.07–0.71) [2]. A short delay between maternal infection and treatment onset significantly
reduced the risk of ocular lesion during a 2-year follow-up [17]. Another study demonstrated
that antenatal treatment significantly reduced the occurrence of severe neurologic sequelae or
death [11]. Prusa-Romana et al. recently reported that antenatal treatment reduces the risk of
mother-to-child transmission when compared with those without treatment [18]. Thus, it is
possible that the greater disease severity observed at birth in the US is in part due to the lack of
antenatal screening and treatment in these children.
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France and US stand as paradigms of the divergent approaches to diagnosing and treating
congenital toxoplasmosis; in reality, they represent a lack of consensus.
Systematic screening programs for all pregnant women at risk are not widely implemented,
despite having been shown to work in several countries. Here we propose that, whatever the
approach chosen (French-like versus USA-like), there are three underlying issues that need to
be addressed by each country or region: parents should be informed about the disease and
how to prevent it; health care providers should have access to state-of-the art information and
guidelines, and counseling should be available at reference centers; and studies should be per-
formed to address the issue of whether antenatal screening programs are cost-effective. There
are some concerns regarding the future financial viability of these programs in light of the
decline in prevalence [5]. However, such programs could be cost-effective even in the US
assuming maternal screening test costs are lower than those currently offered [19]. Efforts
towards reducing the cost of laboratory testing should be a top priority.
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